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1. INTRODUCTION AND LITERATURE REVIEW 
__________________________________________________________ 
 
1.1 Overview of Tuberculosis 
 
Tuberculosis (TB) is a global pandemic issue and the incidence is rising. It is 
accounted for the top ten leading cause of death especially in the middle income countries. 
Globally, according to World Health Organization (WHO), there were an estimated 9.4 
million new cases of TB in 2008 with 140 new cases per 100 000 population. Although the 
total number of new cases of TB is increasing, the number of cases per capita is falling as a 
result of global population growth. However, the rate of decline is very slow, at less than 1% 
per year.  
In many industrialized countries with good treatment facilities and a secured supply of 
drugs free of charge for patients, treatment results have not reached the targets set by WHO 
(Vasankari et al., 2007). The main reason for this is the high rate of death as an unfavourable 
outcome, frequently with much co-morbidity from other diseases.  
Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome 
(HIV/AIDS) is responsible for most increase cases of active TB. In the era of Highly Active 
Anti-Retroviral Therapy (HAART), TB remains the most common opportunistic infection 
and a major cause of death among HIV infected individuals especially in Sub-Saharan Africa 
and Asian countries (Badri et al., 2001, Narain and Lo, 2004). The incidence of active TB is 
more than eight times higher in HIV- positive then HIV-negative (WHO., 2006b). 
Mycobacterium tuberculosis is spread to the public through airborne droplets from 
active person via coughing, sneezing, singing or talking. These infectious particles are very 
small and can remain airborne for minutes to hours (Frieden TR et al., 2003). TB infection 
occurs when the droplets entered the lungs. The bacterium is then taken up by the 
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macrophages, a type of white blood cells and then the inflammatory response will be 
activated. This response will result in either containment of the infection or development of 
active disease (Frieden TR et al., 2003). A healthy immune system is very effective in 
containing TB, but is not able to eradicate it, so that the TB bacilli will remain in the 
macrophages (Chandra et al., 2004). 
In healthy individual who are exposed to the TB, cell mediated immune response will 
react involving T-cells, macrophages and cytokines (Chandra et al., 2004). The infection 
usually controlled unless the immune function is weakened (Frieden TR et al., 2003, 
Wilkinson et al., 2000, Karyadi E et al., 2000, Karyadi et al., 2002). 
1.1.1 Risk factors 
 
There are several factors that can increase the risk for developing active TB. It can be 
divided into environmental and clinical disease with immune-compromised related. The 
common risk factors that contribute to the development of active TB are diabetes mellitus, 
chronic renal failure and also on haemodialysis (Jeon and Murray, 2008),(Segall and Covic, 
2010).  
Other clinical conditions that have been associated with active TB include 
gastrectomy with marked weight loss and malabsorption, jejuno-ileal bypass, renal and 
cardiac transplantation and malignancy ( e.g., lung cancer, lymphoma and leukemia) (Cohn et 
al., 2000). 
Low body weight is another most important risk factor for tuberculosis. A body mass 
index (BMI) below 18.5 increases the risk by 2-3 times as compared to normal BMI. An 
increase in the body weight lowers the risk for developing TB (Leung et al., 2007). 
About 90% of those infected with Mycobacterium tuberculosis have asymptomatic. However, 
if untreated, the death rate for active TB cases is more than 50%. 
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Symptoms include chest pain, coughing up blood, and a productive, prolonged cough 
for more than three weeks. Systemic symptoms include fever, chills, night sweats, appetite 
loss, weight loss, pallor, and fatigue (Frieden TR et al., 2003). 
 
1.1.2 Diagnosis 
Bacteriology remains the recommended method for diagnosing active TB, first 
through sputum smear microscopy then mycobacterium culture and sensitivity (WHO., 2007, 
WHO., 2006b). However, TB culture will not immediately available (WHO., 2007, Frieden 
TR et al., 2003). In countries where the culture is not routinely available, sputum smear will 
be the primary diagnostic tool. However, relying on sputum smears to diagnose TB has its 
own limitations especially among HIV- positive individuals who are generally less likely to 
have positive smear results, particularly in the advance stage (Harries et al., 1998). 
Tuberculin skin test is one of the screening methods for TB. A positive tuberculin test 
indicates that the body has developed cell-mediated immunity against TB (Frieden TR et al., 
2003).  Progression to the active TB can be caused by a recent infection, activation of latent 
TB, or a relapse of earlier treatment (Dye., 2006, C., 2006, WHO., 2006b). 
The newer interferon release assays (IGRAs) such as T-SPOT.TB and QuantiFERON-
TB Gold In Tube overcome many of these problems. IGRAs are in vitro blood tests that are 
more specific than the skin test. IGRAs detect the release of interferon-gamma in response to 
mycobacterial proteins such as ESAT-6 (Nahid et al., 2006). These are not affected by 
immunization or environmental mycobacterium, so generate fewer false positive result (Pai et 
al., 2008). There is also evidence that IGRAs are more sensitive than the skin test (Pai et al., 
2004). 
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New TB tests have been developed that are fast and accurate. These include 
polymerase chain reaction assays for the detection of bacterial DNA  (Reddy et al., 2002).  
The result will be available as fast as 100 minutes. 
Another such test, which was approved by the FDA in 1996, is the amplified 
mycobacterium tuberculosis direct test (MTD, Gen-Probe). This test yields results in 2.5 to 
3.5 hours, and it is highly sensitive and specific when used to test smears positive for acid-
fast bacilli (AFB) (Guerra et al., 2007).  
 
1.1.3 Treatment 
The goals of TB treatment include: 
• Cure of active TB disease without recurrence 
• Prevention of transmission 
• Prevention of drug resistance 
• Improved survival 
Standardized short course chemotherapy is used for 6-8 months in confirmed smear 
positive cases (WHO., 2007). Combinations of drugs therapy with good adherence are 
necessary to achieve a cure.  
The treatment will be divided into two phases. The intensive phase of treatment takes 
around 2-3 months depending on the response. At least three or preferably four daily 
antibacterial drugs regime will use including isoniazide and rifampicin. The maintenance 
phase usually uses two drugs daily or three times a week and lasts 4-6 months (Frieden TR et 
al., 2003). 
Directly observed treatment, short course (DOTS) is an important approach to promote 
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adherence to the treatment (WHO., 2006b). This approach was proved in improving 
completion of anti-TB therapy, reducing multidrug resistant and preventing disease relapse. 
This strategy was further enhanced in The Global Plan to Stop TB. This plan also highlighted 
the issues of TB/HIV co-infection and multidrug resistance, strengthening health systems, 
engaging all providers, empowering individuals with TB and their communities and 
promoting research (WHO., 2006a). 
 
1.2 Overview of Body Mass Index and Nutrition Screening Tools 
Various nutrition screening methods, including subjective global assessment, 
prognostic nutrition index, prognostic inflammatory and nutritional index and nutritional risk 
index require questionnaires or complex scoring system, or are not routinely checked in 
general clinical settings. Moreover, these methods are not used in TB patients for predicting 
disease outcomes. While nutritional predictors of poor prognosis in TB patients have been 
reported in some studies, the parameters are variable and show inconsistent results, 
depending on specific studies and patients (Mehta et al., 1996, Sharma et al., 2006, Zachariah 
et al., 2002) 
Anthropometry is one of the most basic tools for assessing nutritional status, whether 
over nutrition or undernutrition (Mei et al., 2002). A variety of methods are available to 
measure body fatness or thinness however the used was limited due to its complexity and 
cost. The most frequently used tools in public health evaluation and clinical screening are 
anthropometric- based measurement screening such as skinfold-thickness or circumference 
measurements and Body Mass Index (BMI). 
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Body Mass Index (BMI) is defined as the weight in kilograms divided by the square 
of the height in meters. It is a simple and useful index of relative weight that can be used to 
assess obesity or nutritional deficiency (Bailey and Ferro-Luzzi, 1995). 
The association between BMI and mortality has been extensively reported. The 
relationship between Body mass Index is U shaped. Both low and high BMI are associated 
with increased risk of mortality and morbidity in adults (Diehr et al., 2008). 
In Malaysia, there were few studies conducted to evaluate the prevalence of BMI 
among the populations group. The earlier study reported that among adults population in 
Malaysia, 60-64% were normal weight, 11-20 % was underweight and 29-30% was obese 
(Ismail et al., 1995). R Visvanathan et.al reported that approximately 14 % of elderly 
residents had BMI < 18.5 kg/m² (Visvanathan et al., 2004). One study conducted among 
university student showed that the prevalence of BMI  among the groups were normal weight 
61%, underweight 27 % and overweight was 12% (Huda and Ahmad). 
From this report, we can evaluate that the prevalence of underweight and obesity is 
variable among the elderly, adults and teenagers group. With the strong relationship between 
BMI and morbidity, information of BMI can be used as part of evaluation of the health 
burden in our population. 
 
1.3 Overview of Nutrition and Tuberculosis 
Tuberculosis has a dramatic effect on nutritional state and this has been born out in all 
the studies that investigated the association of body composition in affected patients. It has 
been found that malnourished tuberculosis patients have delayed recovery and higher 
mortality rates than well-nourished patients (Gupta et al., 2009). Such malnutrition 
undoubtedly contributes to the mortality and morbidity particularly in resource poor settings. 
Considering the bi-directional relationship, the effect of primary malnutrition on tuberculosis 
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can increase frequency of occurrence and exacerbation of clinical manifestation, both at the 
population and clinical level. Even though the pathophysiology is still not clear, however, in 
addition to good anti-tuberculous therapy, such patients need a nutritional support during the 
treatment or recovery phase. In the developing countries, this may include medical measure 
to achieve nutritional support whereas in resource poor settings, nutritional intake may have 
more to do with equitable resource distribution and community involvement in health care 
(Macallan, 1999). 
 
1.2.1 Malnutrition and immunity 
Nutritional status is one of the most important determinants of treatment outcomes. It 
is well established that nutritional deficiency is associated with impaired immune function 
(Perronne, 1999). Malnutrition will cause weakening of the immune function by reducing cell 
mediated immunity and therefore increase susceptibility to infection (Chandra, 1991). 
Malnutrition is defined as a state of nutrition in which a deficiency or excess (or 
imbalance) of energy, protein and other nutrients causes measurable adverse effects on tissue/ 
body form (body shape, size and composition) and function and clinical outcome (Hickman 
and Tapsell, 2009) 
General malnutrition manifests itself as low weight for height (thinness) and this 
condition is often co-exist with micronutrient deficiency which often referred to as protein 
energy malnutrition or simply as clinical malnutrition.  Generalized malnutrition can cause 
significant impairment involving immune protection’s mechanism including cell-mediated 
immunity, phagocytic function, antibody concentration and cytokine production. 
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1.2.2 Malnutrition and Tuberculosis 
The association between TB and malnutrition has long been known. TB makes 
malnutrition worse and malnutrition weakens immunity, thereby increasing the likelihood 
that latent TB will develop into active disease (Van Lettow et al., 2004). Unfortunately, few 
studies have been designed to examine the relationship between nutrition and the incidence of 
TB or its severity. It is very difficult to determine accurately what the nutritional status of 
individuals with active TB was before the onset of the disease, making it impossible to 
determine whether malnutrition led to advancement of the disease or in reverse theory 
(Cegielski and McMurray, 2004). 
 
1.2.3 Body Mass Index (BMI) and Tuberculosis (TB) 
Several studies showed that patients with active TB are more  likely to have low body 
mass index (BMI=wt(kg)/ht(m²)) compared to healthy individuals (Van Lettow et al., 2004, 
Harries et al., 1988, Paton et al., 2004). World Health Organization (WHO) has classified 
nutritional status based on BMI as shown (table 1). 
During active TB, catabolic processes that cause wasting usually begin before the 
patient is diagnosed; therefore more is known about nutritional status at the time of diagnosis 
than of the wasting process per se (Macallan, 1999). As with HIV infection, at the time of 
diagnosis the metabolic rate or resting energy expenditure is increased, resulting in increased 
energy needs to meet the basic demands for body function. At the same time, energy intakes 
are likely to decline as a result of illness-associated anorexia (Macallan et al., 1998). This 
combination of conditions results in weight loss with eventual wasting if energy intakes are 
not increased or energy expenditure decreased. Utilization of amino acids and protein 
synthesis may be inhibited due to the presence of pro-inflammatory cytokines. 
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Several nutritional parameters are worse among newly diagnosed TB patients 
compared to healthy controls: 
1)  In a study of patients with active TB in the United Kingdom, BMI, muscle mass and 
subcutaneous fat stores were 13%, 13%, and 20% lower, respectively, in those with TB 
compared with healthy age, sex and ethnic matched controls (Onwubalili, 1988). 
2) Similarly, in a study conducted in Malawi, these same parameters were 20% (BMI), 
35% (muscle mass) and 19% (subcutaneous fat) less in subjects with active TB with a larger 
decrease in muscle mass than among the United Kingdom patients (Harries et al., 1988) 
3) In Indonesia, the mean BMI of patients with active TB recently admitted for treatment 
was 20% lower than in controls (BMI of 18.5 ± 3.2 vs. 21.9 ± 2.8 in male, 17.8 ± 3.1 vs. 21.9 
± 3.5 in female patients vs. controls respectively, p<0.01). 66% of patients had a BMI <18.5 
(6 times more frequent than in controls). In addition, weight, skin-fold thickness, mid-upper 
arm circumference (MUAC), fat mass, and fat free mass were all significantly lower in those 
with active TB (Karyadi E et al., 2000). 
4) In an Ethiopian study of 155 patients with active TB (81 HIV-negative and 74 
TB/HIV co-infected) and 31 controls, BMI < 18.5 was common (65.4% of TB patients, 
71.6% of TB/HIV co-infected), and severe malnutrition (BMI< 16) was more common in 
those co-infected (Kassu et al., 2005). 
5) Wasting is associated with increased mortality in those with active TB. In a study of 
1,181 newly diagnosed TB patients in rural Malawi, 57% were underweight (BMI<18.5), 
including 21% with BMI < 16.0. A BMI <17.0, indicating moderate to severe malnutrition, 
was associated with a two-fold increased risk of early death (Zachariah et al., 2002). 
Advanced lung disease was associated with low BMI and fat mass in another Malawian study 
(Van Lettow et al., 2004). 
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Classification 
BMI (kg/m²) 
Principal cut-off points 
Underweight <18.50 
Severe thinness <16.00 
Moderate thinness 16.00-16.99 
Mild thinness 17.00-18.49 
Normal range 18.50-24.99 
Overweight ≥25.00 
Obese ≥30.00 
Table1 International classification of adult underweight,overweight, and obesity according to 
BMI 
Source: Adapted from  WHO, 2004 
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1.2.4 Nutritional status and adverse drug reactions 
The most effective anti-tuberculosis therapy is a combination of isoniazid, rifampicin 
and pyrazinamide for 8 weeks, followed by isoniazide and rifampicin for a further 4-7 
months (Bass Jr et al., 1994). Despite the development of this powerful regime, the treatment 
of tuberculosis continues to be a problem in patients who do not tolerate the drugs (Schaberg 
et al., 1996). This regime is associated with significant adverse drug reactions (ADRs). An 
adverse drug reactions is any undesirable effect of a drug beyond its anticipated therapeutic 
effects occurring during clinical use (Asscher et al., 1995). Common ADRs reported from 
previous trial include skin rash and prutritus, hepatitis, nausea/ vomiting, thrombocytopenia, 
influenza- like illness, athralgia and neuropsychiatric symptoms (Forget and Menzies, 2006). 
Predicting the risk factors for adverse drug reactions to first-line TB therapy can assist 
in identifying patient who required proper monitoring to prevent potential morbidity, 
hospitalization and mortality. Previous studies shown that female sex, age> 60 years, Asian 
birth, low body mass index/ malnutrition and Human Immunodeficiency Virus (HIV) 
infection have been suggested to be associated with an increased incidence of ADRs to first-
line TB medications (Yee et al., 2003). Malnutrition will result in decreased drug clearance so 
that increased the plasma level and subsequently increased the risk of ADRs. (Walter-Sack 
and Klotz, 1996). 
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 1.2.5 Nutritional treatment of tuberculosis 
Nutritional supplementation may help to improve outcome in tuberculosis patients. A 
study found that nutritional counseling to increase energy intake combined with provision of 
supplements, when started during the initial phase of tuberculosis treatment produced a 
significant increase in body weight, total lean mass and physical function after 6 weeks. In 
the same study, patients in the nutritional supplementation group continued to show a greater 
increase in body weight than control subjects during later follow-up (Paton et al., 2004). 
Vitamins and mineral can play important role in treatment of tuberculosis. One trial 
showed that vitamins C and E were effective in improving immune responses to tuberculosis 
when given as adjuvant to multidrug tuberculosis therapy (Safaryan et al., 1990). The 
supplementation with vitamin A and zinc improved the effectiveness of the anti-tuberculosis 
drugs in the first two months. The improved outcome was indicated by the higher number of 
patients with sputum negative for bacilli and significantly lower mean lesion area in the lungs 
(Karyadi et al., 2002). 
Nutritional supplementation may represent a novel approach for fast recovery in 
tuberculosis patients. In addition, raising nutritional status of population may prove to be an 
effective measure to control tuberculosis in underdeveloped areas of world. 
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2  PURPOSE OF THE STUDY 
 
Tuberculosis is pandemic globally and the incidence is rising. According to WHO 
2010/2011 TB Global Facts Update, about 1.7 million people died from TB in 2009 and TB 
among the three greatest causes of death among women 15 to 44 years old. Based on the data, 
Malaysia is one of the high burden country of tuberculosis. Predicting clinical outcomes 
among TB patients receiving anti-TB treatment under Directly Observed Treatment, Short 
course (DOTS) strategy helps in recognizing cases that are more likely to fall in the treatment 
failure group.  
In Malaysia, a routine procedure used for diagnosing new PTB cases is sputum smear 
microscopy. The approach in which every suspected TB case should submit 3 sputum 
specimens for smear microscopy examination. Persistent smear positive at the end of 2nd 
month has been cited as one of the predictor for treatment failure (Jeremiah, 2009). 
The adverse effects of anti-tuberculosis is a potentially serious issues of the currently 
antituberculosis antituberculosis chemotherapeutic regimens. The new regimen is divided 
into 2 months of intensive phase and 4 months of continuation phase. In this regimen drugs 
are given to patients in a fix dose combination (FDC) of 4 drugs (streptomysin,rifampicin, 
isoniazid, pyrazinamide or ethambutol) during the 2 months of intensive phase and 2 drugs in 
aFDC (rifampicin, isoniazid) during the 4 month of continuation phase . In general, anti-TB 
drugs are effective and most TB patients are cured. However, it is a challenge that some 
patients will develop anti-tuberculosis drug induced reactions after starting the regimes. 
Various studies in different settings worldwide have tried to identify factors that may be 
associated with adverse drug reactions with anti-tuberculosis, however the underlying 
mechanisms and the factors predisposing to its development are not clearly understood. 
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Beside the increase cases of HIV positive patients among PTB cases, other risk factors 
that were observed for developmenting of active tuberculosis are immunosuppress people 
such as Diabetis Mellitus, chronic kidney failure and low BMI. In general, low BMI has a 
strong relationship with risk of tuberculosis and high BMI has been shown to be protective 
against tuberculosis (TB) among HIV negative individuals, as well as against disease 
progression and mortality among those with HIV.  
Since the association between low BMI and development TB is well recognised 
(Tverdal, 1986, Leung et al., 2007, Maro et al., 2010), this study may have identified the use 
of BMI to predicts clinical outcomes of PTB, so that this relatively simple measurement can 
be used for clinical benefit especially in resource limited setting. With this objective in mind, 
the present study was aimed at clarifying the association  of the BMI with the clinical 
outcomes of PTB patients and subsequently help in improving the treatment outcomes among 
PTB patients. 
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3 OBJECTIVES 
 
3.1  General Objective 
To determine the association of Body Mass Index (BMI) and clinical outcomes among PTB 
patients in Hospital Universiti Sains Malaysia (HUSM).  
 
3.2 Specific Objectives 
3.2.1 To examine the association between baseline BMI and sputum conversion at the end 
of 2 months after initiation of anti-tuberculosis treatment in smear positive sputum 
patients. 
 
3.2.2 To examine the association between baseline BMI and weight gain after 2 months of 
initiation of anti-tuberculosis treatment. 
3.2.3  To examine the association of baseline BMI and adverse drug reactions in PTB 
patients during intensive phase of anti-tuberculosis treatment. 
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4 METHODOLOGY 
 
4.1 Study Population 
The study was conducted in Hospital Universiti Sains Malaysia (HUSM), Kubang Kerian, 
Kelantan from May 2010 to May 2011. The source population for this study will be all the 
cases who were notified as pulmonary TB in HUSM and at least 6 months on anti 
tuberculosis therapy. 
 
4.2 Inclusion and Exclusion Criteria 
Inclusion criteria    :   
- Pulmonary Tuberculosis patients recruited at the Respiratory Clinic, Hospital Universiti   
   Sains Malaysia (HUSM) 
- Age 15 to 65 years old. 
Exclusion criteria   : 
- Patients with extrapulmonary TB alone. 
-Human Immunodeficiency Virus patients 
- Pregnant women 
- Terminal illnesses ( from tuberculosis and any other severe diseases which unlikely to   
  survive within 48 hours). 
- Not willing to participate. 
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4.3 Estimated Sample Size 
Sample size was calculated using PS- Power and sample size calculation software version 3.0.43 
with two proportion formula. 
a) Sputum conversion rate (Su et al., 2011) 
The proportion of patients in normal group who had sputum conversion was 0.70 and among 
low BMI group was 0.30. 95% confidence interval was targetted to be 0.05 with power of the 
study was 80 %. 
Estimated sample size by software : 20 x 2 = 40 samples 
 
b) Adverse drug reactions (Tan et al., 2007) 
The proportion of patients in normal group who had adverse drug reactions  was 0.30 and 
among low BMI group was 0.53. 95% confidence interval was targetted to be 0.05 with 
power of the study was 80 %. 
Estimated sample size by software : 76 x 2 = 156 samples 
 
From this calculation, estimated sample size for this study was 156 samples. 
 
4.4 Sampling Method 
All PTB patients who were notified in HUSM from May 2010 to May 2011 that fulfill the 
criteria were recruited in this study. Simple sampling technique was used to recruit the 
patients. 
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4.5 Research Tools 
Patients  who were registered as  pulmonary TB in our institution between May 2010  
till May  2011 were identified from the respiratory clinic. The patient’s notes were reviewed 
with regards to inclusion and exclusion criteria. A structured questionnaire and record form 
were used to gather information on basic demoghraphic data, risk factors and type of TB. 
Weight of the patient upon diagnosis was gained from TB file and subsequent follow-up with 
digital weighing scale. Height was measured with the patient standing upright and looking 
straight ahead using tape measure. All patients gived written consent to participate in the 
study. 
  Data for the clinical outcomes (sputum conversion, weight gain and adverse drug 
reactions) gathered and observed during the study duration. For the sputum conversion and 
weight gain, data will be collected at 2 months of treatment and data for adverse drug 
reactions will be gathered at 6 months duration of treatment. Only sputum positive patients 
will be included in the data analysis of sputum conversion outcome.  
 
4.6 Statistical Analysis 
 
Data entries and analyses of results will be done using the SPSS for Windows (version 18.0, 
SPSS Inc., Chicago) statistical software package.  
The demographic data were analyzed using descriptive statistics and reported as mean, 
standard deviation and percentages.  
Association between BMI and clinical outcomes was analyzed by using simple and 
multivarite analysis.  
P-value <0.05 is a significant value. 
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4.7 Definition of Terms 
 
1) Pulmonary Tuberculosis (PTB) (WHO 2009)  
PTB refers to a case of TB  involving the lung parenchyma with or without extrapulmonary 
TB. 
 
2) Clinical Outcomes of Pulmonary TB 
Sputum conversion ( Malaysia CPG, 2nd edition,2002) 
Smear positive response :  
Achievement of conversion of initial smear positive patient to a  smear negative sputum at 
the end of 2 months of the anti-TB treatment. 
Smear negative response : 
Persistent  sputum smear positive at the end of 2 months of the anti-TB treatment.                       
 
Adverse drug reactions (Chhetri et al., 2008) 
An undesirable response associated with the use of anti-TB drugs. Some common ADRs due 
to anti-tuberculous drugs are drug induced hepatitis, skin rashes, opthalmic involvement, 
hearing impairement, peripheral neuropathy, pancreatitis, ototoxicity, hyperuricaemia and 
hypersensitivity reactions.  
 
Drud induced hepatitis (Yee et al., 2003) 
Hepatitis was defined as liver transaminase more than three times higher than the upper limit 
of normal in the presence of symptoms such as anorexia, nausea, vomiting or abdominal pain, 
or transaminases more than five times the upper limit of normal without symptoms. Episodes 
of hepatitis were considered drug induced if transaminases were normal before therapy, 
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increased during therapy, and returned to normal after discontinuation of anti-TB. 
 
3) Body Mass Index ( BMI): (WHO,2004) 
It is defined as the weight in kilograms divided by the square of the height in metres (kg/m2) 
Obesity: ≥ 30.00 kg/m² 
Overweight:≥25.00 kg/m² 
Normal BMI:18.50-24.99 kg/m²  
Underweight :<18.50 kg/m² 
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4.8 Flow Chart 
 
 
 
 
                                                                                                                           
       
 
 
 
 
 
Reference Population : 
Registered PTB patients in HUSM 
Source Population : 
PTB patients who receive follow-up from the Respiratory Clinic,HUSM 
Samples 
recruitment 
Consent form given to the samples 
Data collection : 
Record review 
BMI calculation 
Data entry, analysis and interpretation 
Report and paper preparation for presentation 
Submission of research paper 
      Follow- up 
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5 RESULTS AND DATA ANALYSIS 
 
 
 
5.1 Characteristic of the study population 
 
 
During the study period, a total of 127 patients were recruited for this study. The total of 
estimated sample size (156) cannot be recruited due to time constraint. 
 The mean age of presentation was 44.74 ± 17.38 years. The study population had male 
predominant (53.1%) and Malay’s ethnic contributed to the highest proportion of the study subjects 
(96.9%). A quarter (26.6%) of patients did not have formal education  level and 36.7% had either  
primary or secondary education's level. Other than that, patient had background of college or 
university level, 25.0% and 10.9% respectively. 
 Majority of patients were newly diagnosed pulmonary tuberculosis which contributes to 
96.1% (n=123) and only 3.1% (n=4) were reactivation of pulmonary tuberculosis. From this, there 
were 63.3% (n=81) pulmonary smear positive, 35.2% (n=45) pulmonary smear negative and 0.8% 
(n=1) miliary tuberculosis. 
 Most of the patients did not have any risk factors or co-morbidities, while others had 
comorbidities which were diabetes mellitus 17.2% (n=22), hypertension 2.3% (n=3) , hepatitis B 
0.8% (n=1) and others 3.1% (n=4). Chronic obstructive pulmonary disease (COPD) and chronic 
lung disease were included in the others. However there were 18 patients who had comorbidities 
more than 1 in which combination of diabetis mellitus, hypertension and end stage renal failure.  
Majority of patient were non-smokers, 63.3% (n=81) while others, 35.9% (n=46) were  smokers. 
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Table 2: Study population demoghraphic (n=127) 
      
 Variables        frequencies,n (%)  Mean  Standard Deviation 
 
Age        44.74   17.383 
 
Race 
 
       Malay    124(96.9)          
 
        Chinese   1(0.8) 
 
         others    2(1.6)         
 
 
Gender 
 
         Male          68(53.1) 
 
         Female   59(46.1) 
 
 
Education 
 
        no formal education  34(26.6) 
 
         primary/secondary school 47(36.7) 
 
            college   32(25.0) 
 
         university   14(10.9) 
 
Smoking status 
  
smoker   46(35.9) 
 
        non smoker   81(63.3) 
 
Type of pulmonary  
tuberculosis 
 
smear positive   81(63.3) 
 
smear negative  45(35.2) 
 
miliary   1(0.8) 
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table 2 continued 
 
 
 
Status of pulmonary 
tuberculosis 
 
new    123(96.1) 
 
reactivation/   4(3.1) 
relapse 
 
Co-morbidities 
 
nil    79(61.3) 
 
Hypertension   3(2.3) 
 
Hepatitis B/C   1(0.8) 
 
Diabetis mellitus  22(17.2) 
 
Others    4(3.1) 
 
>1    18(14.1) 
 
BMI status       19.50  3.88 
(baseline) 
 
Obese    2(2.0) 
 
Overweight   10(7.4) 
 
Normal   50(41.2) 
 
Underweight   65(49.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
